胰高糖素样肽-1受体激动剂的潜在肾脏保护作用探讨  

Potential kidney protective effects of GLP-1 receptor agonist

作　　者：吴金珊 李启富[1] WU Jin-shan;LI Qi-fu(Department of Endocrinology,The First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)

机构地区：[1]重庆医科大学附属第一医院内分泌内科,重庆400016

出　　处：《药品评价》2020年第S01期28-32,37,共6页Drug Evaluation

摘　　要：糖尿病肾病是糖尿病最常见的微血管并发症之一,严重危害着人类健康。目前临床治疗药物虽能部分延缓其进展,但效果仍不理想。胰高糖素样肽-1受体激动剂(glucagon-like peptide-1 receptor agonist,GLP-1 RA)作为一种新型降糖药物,不仅能通过促进胰岛素分泌降低血糖,还能降低蛋白尿,延缓估算肾小球滤过率(estimated glomerular filtration rate,eGFR)的下降,起到肾脏保护作用。但其具体机制尚不清楚,可能是多种机制共同作用的结果。本文从直接和间接作用两方面对其潜在机制进行探讨。Diabetic kidney disease is one of the most common microvascular complications of diabetes,which is seriously harmful to human health.At present,clinical drugs can partially delay its progress,but the effect is still not satisfied.As a new type of anti-diabetic drug,GLP-1 receptor agonist can not only promote insulin secretion and reduce blood glucose,but also reduce proteinuria,delay the decline of eGFR,and play a protective role in kidney.However,the specific mechanism is not clear,which may be the result of the joint action of a variety of mechanisms.This paper discusses its potential mechanism from both direct and indirect aspects.

关 键 词：糖尿病肾病 胰高糖素样肽-1受体激动剂 肾脏保护 

分 类 号：R587.1[医药卫生—内分泌]